Optimal clinical trial design using value of information methods with imperfect implementation

Health Economics

Volumn 19, Issue 5, 2010, Pages 549-561

  Willan, Andrew R ^a   Simon, Eckermann ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Imperfect implementation; Optimal trial design; Value of information

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PLACEBO;

ADULT; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DYSPEPSIA; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; METHODOLOGY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 77951722695     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1493     Document Type: Article

References (20)

1. Chiba N, van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. 2002. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. British Medical Journal 324: 1012-1016. (Pubitemid 34457514)
2. Claxton K. 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18: 341-364. (Pubitemid 29242816)
3. Claxton K, Posnett J. 1996. An economic approach to clinical trial design and research priority setting. Health Economics 5: 513-524. (Pubitemid 126478560)
4. Claxton K, Thompson KM. 2001. A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics 20: 797-822. (Pubitemid 32743392)
5. Eckermann S, Willan AR. 2007. Expected value of information and decision making in HTA. Health Economics 16: 195-209. (Pubitemid 46206613)
6. Eckermann S, Willan AR. 2008a. Time and EVSI wait for no patient. Value in Health 11: 522-526.
7. Eckermann S, Willan AR. 2008b. The option value of delay in health technology assessment. Medical Decision Making 28: 300-305. (Pubitemid 351713293)
8. Eckermann S, Willan AR. 2009. Globally optimal trial design for local decision making. Health Economics 18: 203-216.
9. Fenwick E, Claxton K, Sculpher M. 2008. The value of implementation and the value of information: combined and uneven development. Medical Decision Making 28: 21-23.
10. Halpern J, Brown Jr BW, Hornberger J. 2001. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Statistics in Medicine 20: 841-858. (Pubitemid 32249084)
11. Hornberger JC, Brown Jr BW, Halpern J. 1995. Designing a cost-effective clinical trial. Statistics in Medicine 14: 2249-2259.
12. Hornberger J, Eghtesady P. 1998. The cost-benefit of a randomized trial to a health care organization. Controlled Clinical Trials 19: 198-211. (Pubitemid 28191974)
13. Hutton EK, Kaufman K, Hodnett E, Amankwah K, Hewson SA, McKay D, Szalai JP, Hannah ME. 2003. External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. American Journal of Obstetrics and Gynecology 189: 245-254. (Pubitemid 36886558)
14. Kikuchi T, Pezeshk H, Gittins J. 2008. A Bayesian cost - benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 27: 68-82. (Pubitemid 351193660)
15. Willan AR. 2004. Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. European Journal of Gastroenterology and Hepatology 16: 543-549.
16. Willan AR. 2007. Clinical decision making and the expected value of information. Clinical Trials 4: 279-285. (Pubitemid 47400539)
17. Willan AR. 2008. Optimal sample size determinations from an industry perspective based on the expected value of information. Clinical Trials 5(6): 587-594.
18. Willan AR, Briggs AH. 2006. The Statistical Analysis of Cost-effectiveness Data. Wiley: Chichester.
19. Willan AR, Kowgier ME. 2008. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clinical Trials 5: 289-300.
20. Willan AR, Pinto EM. 2005. The expected value of information and optimal clinical trial design. Statistics in Medicine 24: 1791-1806. Correction: Statistics in Medicine 2006; 25: 720.